Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of their abstract at the upcoming Leipzig Interventional Course (LINC) 2026, being held January 27-30, 2026, in Leipzig, Germany ...

Core Insights - Profusa, Inc. is set to present a Late Breaking Clinical Trial Update on its Lumee™ Oxygen tissue monitoring platform at the Paris Vascular Insights (PVI) 2025 conference, highlighting its innovative technology for continuous monitoring of tissue oxygen in patients with peripheral artery disease [1][2] - The Lumee technology allows for real-time measurement of tissue oxygen levels directly within the body, representing a significant advancement in biochemistry monitoring for both clinical and home use [2][3] - Profusa aims to provide personalized biochemical data through its long-lasting, injectable biosensors, which are designed to deliver actionable medical-grade information for both personal and medical applications [3] Presentation Details - The presentation titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" will be delivered by Dr. Peter Schneider on December 13, 2025, at 1pm CET [2] - The event will take place at the Carrousel du Louvre in Paris, France, showcasing the latest innovations in vascular and endovascular surgery [2] Company Overview - Profusa is based in Berkeley, California, and is recognized for its pioneering work in developing tissue-integrated sensors that continuously transmit reliable biochemical data [3] - The company is led by a team of experienced professionals and aims to create a new generation of affordable biosensors that enhance patient care through personalized data [3]

Core Insights - Profusa, Inc. has expanded its commercial footprint in Europe for its Lumee Oxygen platform by signing a letter of intent with Angiopro GmbH, targeting initial markets such as Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia [1][3] - The partnership with Angiopro enhances Profusa's distributor channel coverage to approximately 35% of the European Union population, facilitating around 300,000 annual endovascular procedures [1][3] - Profusa's Lumee platform technology addresses a global market estimated at over $10.5 billion across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical-grade data [4] - The company aims to deliver long-lasting, injectable, and affordable biosensors, creating a personalized biochemical signature for individuals [4] Partnership Details - Angiopro GmbH is a specialized MedTech distributor with expertise in cardiovascular technologies, aiming to enhance patient care and drive commercial success [2] - The collaboration is expected to leverage Angiopro's marketing, sales infrastructure, and regulatory expertise to establish a strong foundation for long-term growth with Profusa [2]